Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TMB-H
i
Other names:
TMB | Tumor Mutational Burden
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Others
‹
›
Related tests:
FoundationOne® CDx (106)
FoundationOne® CDx (106)
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
TMB-H
Soft Tissue Sarcoma
TMB-H
Soft Tissue Sarcoma
nivolumab
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
nivolumab
Sensitive
:
A2
NCCN - 2wk
nivolumab
Sensitive: A2 - Guideline
NCCN - 2 weeks
nivolumab
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
TMB-H
Soft Tissue Sarcoma
TMB-H
Soft Tissue Sarcoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 2wk
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 2 weeks
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
TMB-H
Soft Tissue Sarcoma
TMB-H
Soft Tissue Sarcoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
pembrolizumab + ipilimumab
Sensitive
:
A2
NCCN - 2wk
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 2 weeks
pembrolizumab + ipilimumab
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
TMB-H
Ovarian Cancer
TMB-H
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
AACR 2023 - 2 weeks (New B)
ABT-888
Sensitive
:
B
AACR 2023 - 2wk
ABT-888
Sensitive: B - Late Trials
AACR 2023 - 2 weeks
ABT-888
Sensitive
:
B
AACR 2023 - 2 weeks - (New B)
TMB-H
Gastric Cancer
TMB-H
Gastric Cancer
pembrolizumab
Sensitive: A2 - Guideline
AACR 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
A2
AACR 2023 - 2wk
pembrolizumab
Sensitive: A2 - Guideline
AACR 2023 - 2 weeks
pembrolizumab
Sensitive
:
A2
AACR 2023 - 2 weeks - (New C3)
TMB-H
Soft Tissue Sarcoma
TMB-H
Soft Tissue Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 2wk
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 2 weeks
pembrolizumab
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
TMB-H
Non Small Cell Lung Cancer
TMB-H
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C1 - Off-label
AACR 2023 - 2 weeks (New D)
pembrolizumab
Sensitive
:
C1
AACR 2023 - 2wk
pembrolizumab
Sensitive: C1 - Off-label
AACR 2023 - 2 weeks
pembrolizumab
Sensitive
:
C1
AACR 2023 - 2 weeks - (New D)
TMB-H
Gastric Cancer
TMB-H
Gastric Cancer
nivolumab
Sensitive: C3 – Early Trials
AACR 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
AACR 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
AACR 2023 - 2 weeks
nivolumab
Sensitive
:
C3
AACR 2023 - 2 weeks - (New C3)
TMB-H
Non Small Cell Lung Cancer
TMB-H
Non Small Cell Lung Cancer
dostarlimab
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
dostarlimab
Sensitive
:
D
AACR 2023 - 2wk
dostarlimab
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
dostarlimab
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
TMB-H
Biliary Tract Cancer
TMB-H
Biliary Tract Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 3wk
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 3 weeks
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
TMB-H
Solid Tumor
TMB-H
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
TMB-H
Peritoneal Cancer
TMB-H
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Testicular Seminoma
TMB-H
Testicular Seminoma
TIP
Sensitive: A2 - Guideline
TIP
Sensitive
:
A2
TIP
Sensitive: A2 - Guideline
TIP
Sensitive
:
A2
TMB-H
Sarcoma
TMB-H
Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Chordoma
TMB-H
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Germ Cell Tumors
TMB-H
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Thyroid Gland Follicular Carcinoma
TMB-H
Thyroid Gland Follicular Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Thyroid Gland Medullary Carcinoma
TMB-H
Thyroid Gland Medullary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Endometrial Cancer
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Cervical Cancer
TMB-H
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Thyroid Gland Papillary Carcinoma
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Non Small Cell Lung Cancer
TMB-H
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
TMB-H
Breast Cancer
TMB-H
Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Melanoma
TMB-H
Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
TMB-H
Solid Tumor
TMB-H
Solid Tumor
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
TMB-H
Ewing Sarcoma
TMB-H
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Osteosarcoma
TMB-H
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Penile Cancer
TMB-H
Penile Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Thyroid Gland Anaplastic Carcinoma
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Gastroesophageal Junction Adenocarcinoma
TMB-H
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Esophageal Cancer
TMB-H
Esophageal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Pancreatic Adenocarcinoma
TMB-H
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Ovarian Cancer
TMB-H
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Fallopian Tube Cancer
TMB-H
Fallopian Tube Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Neuroendocrine Tumor
TMB-H
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Testicular Cancer
TMB-H
Testicular Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Vulvar Cancer
TMB-H
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Prostate Cancer
TMB-H
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Nasopharyngeal Carcinoma
TMB-H
Nasopharyngeal Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Biliary Tract Cancer
TMB-H
Biliary Tract Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Head and Neck Cancer
TMB-H
Head and Neck Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login